Peptide 'glow up' claims on TikTok: what the science says

What's this video probably claiming?

Based on the caption, hashtags, and the creator's known content category, @realaxiomlabs is almost certainly pitching peptide therapy as a fast-track to physical transformation. The "glow up" framing is a reliable tell: expect claims about skin quality, fat loss, recovery acceleration, and possibly improved sleep or energy. Creators in this space frequently name-drop BPC-157, GHK-Cu, and GH secretagogues like CJC-1295 or ipamorelin as a package deal, implying synergistic benefits without defining what "synergistic" means in a clinical context. The self-congratulatory "We're the best" caption suggests this is promotional content for a peptide vendor, which adds another layer of scrutiny. Promotional health content on TikTok is not required to meet the same evidentiary standards as peer-reviewed research, and that gap matters a lot when the products in question are unregulated, largely unstudied in humans, and frequently obtained from compounding pharmacies operating in a legal gray zone.

What does the science actually show?

The honest answer is: not much, at least in humans. BPC-157 has a reasonably interesting animal literature. Sikiric et al. (2018, Current Pharmaceutical Design) documented accelerated tendon-to-bone healing in rat models at doses of 10 mcg/kg, but there are zero published randomized controlled trials in humans as of mid-2025. GHK-Cu, the copper peptide often marketed for skin rejuvenation, has some in vitro data showing collagen stimulation (Pickart & Margolina, 2018, Symmetry), but in vitro is not skin. CJC-1295 combined with ipamorelin does meaningfully raise growth hormone pulse amplitude. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 increased IGF-1 levels by 28 to 39 percent over 28 days, but that study used pharmaceutical-grade material in a controlled hospital setting, not a compounded product bought from a wellness vendor. MK-677, technically a growth hormone secretagogue and not a true peptide, increased lean mass in elderly subjects by roughly 1.6 kg over 12 months (Murphy et al., 1998, JAMA), but also increased fasting glucose and appetite substantially.

Where does the social media noise diverge from clinical reality?

Social media peptide content almost always commits three errors simultaneously. First, it conflates animal data with human outcomes. A rat healing faster after BPC-157 injection tells you the molecule is biologically active in mammals. It does not tell you that a subcutaneous injection of compounded BPC-157 will fix your shoulder. Second, it ignores dose-response complexity. Peptides are not vitamins. The margin between a pharmacologically active dose and a waste-of-money dose, or a potentially harmful dose, is not something a TikTok video can navigate responsibly. Third, it treats "peptide" as a monolithic category of wellness supplements, when in reality these are investigational compounds with distinct mechanisms, risk profiles, and regulatory statuses. TB-500, for instance, is a thymosin beta-4 fragment. The World Anti-Doping Agency has it on the prohibited list. Semax and selank are Russian-origin neuropeptides with almost no English-language clinical trial data. Lumping these together under a "glow up" hashtag is not science communication. It is marketing.

What should you actually know?

If you are genuinely interested in peptide therapy, the conversation belongs in a licensed clinician's office, not a comments section. A few things worth internalizing before you act on any TikTok peptide content. Compounded peptides are not FDA-approved drugs. Their purity, concentration, and sterility are only as reliable as the compounding pharmacy producing them, and quality varies substantially. The FDA has taken enforcement action against multiple peptide suppliers in recent years, specifically citing BPC-157 and TB-500 as substances that cannot be legally compounded under current rules. Growth hormone secretagogues like CJC-1295 and ipamorelin can affect insulin sensitivity and may interact with existing metabolic conditions. Anyone with a history of cancer should approach GH-axis stimulation with particular caution, given IGF-1's known role in cell proliferation. And finally: a vendor who calls themselves "the best" in their own caption is not a neutral source of clinical information.